Silo Pharma Inc (SILO)

$0.87 -0.28 (-24.35%)
Market Cap 5.16M
Revenue (ttm) 70,000.00
Net Income (ttm) -4.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,271.43%
Debt to Equity Ratio 0.00
Volume 947,300
Avg Vol 97,566
Day's Range N/A - N/A
Shares Out 4.48M
Stochastic %K 80%
Beta 0.20
Analysts Strong Sell
Price Target $10.00

Latest News on SILO

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Apr 28, 2025, 7:50 AM EDT - 7 hours ago

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Mar 26, 2025, 8:40 AM EDT - 4 weeks ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Feb 26, 2025, 1:30 PM EST - 2 months ago

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Feb 18, 2025, 8:50 AM EST - 2 months ago

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Feb 11, 2025, 7:45 AM EST - 2 months ago

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Jan 22, 2025, 8:29 AM EST - 3 months ago

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Jan 2, 2025, 8:45 AM EST - 4 months ago

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Dec 18, 2024, 7:35 AM EST - 4 months ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Nov 29, 2024, 8:05 AM EST - 5 months ago

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Nov 18, 2024, 8:40 AM EST - 5 months ago

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Oct 31, 2024, 8:35 AM EDT - 6 months ago

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Sep 10, 2024, 6:35 AM EDT - 8 months ago

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Aug 14, 2024, 2:30 PM EDT - 9 months ago

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Aug 7, 2024, 8:13 AM EDT - 9 months ago

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Jul 26, 2024, 8:20 AM EDT - 9 months ago

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 22, 2024, 4:45 PM EDT - 9 months ago

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 19, 2024, 8:01 AM EDT - 10 months ago

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug

Jul 18, 2024, 12:44 PM EDT - 10 months ago

Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Jul 18, 2024, 8:25 AM EDT - 10 months ago

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?

Jul 16, 2024, 10:50 AM EDT - 10 months ago

Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

Jul 16, 2024, 6:30 AM EDT - 10 months ago

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Jun 26, 2024, 8:50 AM EDT - 10 months ago

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

Jun 7, 2024, 8:18 AM EDT - 11 months ago

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jun 6, 2024, 4:50 PM EDT - 11 months ago

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Jun 4, 2024, 8:41 AM EDT - 11 months ago

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

May 21, 2024, 8:45 AM EDT - 1 year ago

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine

May 14, 2024, 8:45 AM EDT - 1 year ago

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

Apr 23, 2024, 8:15 AM EDT - 1 year ago

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic

Apr 10, 2024, 8:11 AM EDT - 1 year ago

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Mar 18, 2024, 7:15 AM EDT - 1 year ago

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Feb 28, 2024, 8:25 AM EST - 1 year ago

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Feb 14, 2024, 8:45 AM EST - 1 year ago

Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Feb 1, 2024, 10:00 AM EST - 1 year ago

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Silo Pharma Announces Positive Results in Alzheimer's Disease Study

Jan 24, 2024, 8:55 AM EST - 1 year ago

Silo Pharma Announces Positive Results in Alzheimer's Disease Study

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

Jan 4, 2024, 8:55 AM EST - 1 year ago

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

Dec 28, 2023, 8:25 AM EST - 1 year ago

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Nov 21, 2023, 8:01 AM EST - 1 year ago

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Nov 8, 2023, 8:11 AM EST - 1 year ago

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Oct 16, 2023, 8:11 AM EDT - 1 year ago

Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD

Oct 11, 2023, 8:35 AM EDT - 1 year ago

Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Sep 20, 2023, 8:28 AM EDT - 1 year ago

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Sep 12, 2023, 8:50 AM EDT - 1 year ago

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

Aug 10, 2023, 8:50 AM EDT - 1 year ago

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers

Jun 23, 2023, 9:00 AM EDT - 2 years ago

Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers

Silo Pharma's SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent

Jun 21, 2023, 9:00 AM EDT - 2 years ago

Silo Pharma's SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent

Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic

Jun 13, 2023, 8:05 AM EDT - 2 years ago

Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Jun 2, 2023, 8:50 AM EDT - 2 years ago

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

May 30, 2023, 9:00 AM EDT - 2 years ago

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Silo Pharma's SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer's Disease

May 9, 2023, 8:05 AM EDT - 2 years ago

Silo Pharma's SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer's Disease

Silo Pharma to Present at Psychedelic Drug Development Conference

Apr 24, 2023, 8:15 AM EDT - 2 years ago

Silo Pharma to Present at Psychedelic Drug Development Conference